Allt inom Regulatory

Nanexa publishes interim report for January-June 2025

The second quarter of 2025 has continued to validate our core belief at Nanexa that slow-release medicines can transform how we dose and therefore treat people living with a range of conditions. Reducing the frequency of injections will improve compliance, treatment outcomes, and quality of life for patients.

Bulletin from Nanexa’s Annual General Meeting

The Annual General Meeting (AGM) of Nanexa AB (publ) has been held on May 15, 2025, at which meeting submitted proposals were passed. The complete proposals for resolutions are set out in the AGM notice.